MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Gross Profit 2011-2026 | NDRA
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 6.17 K | 179 K | 280 K | 744 K | 300 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 744 K | 6.17 K | 302 K |
Quarterly Gross Profit ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.17 K | - | 169 K | 6.34 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 169 K | 6.17 K | 60.4 K |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 17.82 | - | $ 950 M |  USA |
 |
Agilent Technologies
A
|
2.84 B | $ 114.84 | - | $ 34.9 B | USA |
 |
Co-Diagnostics
CODX
|
400 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 168.22 | - | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
53 M | $ 24.73 | - | $ 687 M | USA |
 |
Danaher Corporation
DHR
|
14.5 B | $ 192.12 | - | $ 137 B | USA |
 |
DexCom
DXCM
|
2.8 B | $ 63.21 | - | $ 24.7 B | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
144 M | $ 89.66 | - | $ 11.2 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 109.62 | - | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
24.1 M | $ 1.97 | - | $ 8.72 M | USA |
 |
Illumina
ILMN
|
2.86 B | $ 127.74 | - | $ 20.3 B | USA |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 274.46 | - | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
942 M | $ 75.89 | - | $ 5.12 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 16.3 | - | $ 175 M |  China |
 |
Medpace Holdings
MEDP
|
246 M | $ 496.0 | - | $ 14.3 B | USA |
 |
Aspira Women's Health
AWH
|
5.92 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | USA |
 |
Myriad Genetics
MYGN
|
577 M | $ 4.67 | - | $ 432 M | USA |
 |
NeoGenomics
NEO
|
314 M | $ 8.02 | - | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
421 M | $ 9.56 | - | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 17.33 | - | $ 388 M | USA |
 |
Natera
NTRA
|
127 M | $ 204.87 | - | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Pacific Biosciences of California
PACB
|
45.8 M | $ 1.42 | - | $ 426 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
10.7 M | $ 25.98 | 2.28 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
22.1 M | $ 6.58 | - | $ 390 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
Sotera Health Company
SHC
|
646 M | $ 14.87 | - | $ 4.22 B | USA |
 |
Soleno Therapeutics
SLNO
|
-58.5 K | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
72.3 M | $ 1.76 | - | $ 116 M | USA |
|
Biodesix
BDSX
|
18.5 M | $ 15.36 | - | $ 1.99 B | USA |
 |
Thermo Fisher Scientific
TMO
|
11.3 B | $ 488.19 | - | $ 184 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 27.2 | -0.04 % | $ 20 B |  Niderland |
 |
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.62 | - | $ 61.9 M | Irlanda |
 |
Waters Corporation
WAT
|
1.4 B | $ 304.09 | - | $ 18.1 B | USA |
 |
Exagen
XGN
|
38.8 M | $ 3.08 | - | $ 66.4 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.3 B | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
83.8 K | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
498 K | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.15 | - | $ 6.26 M | USA |